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The interleukin-6 174promoter polymorphism is associated erties [1–3]. It has been shown that IL-6 derived from
with long-term kidney allograft survival. antigen-presenting cells is able to initiate the polarization
Background. Th1-dependent effector mechanisms may be re- of naive CD4 T cells to effector Th2 cells, therebysponsible for allograft rejection. Recently, interleukin-6 (IL-6)
antagonizing differentiation into Th1 cells [4]. Since Th1-has been shown to antagonize CD4 T cells to effector Th2
dependent effector mechanisms are held responsible forcells and, in the process, differentiate them into Th1 cells.
Methods. To assess the role of IL-6 in long-term allograft allograft rejection, IL-6 may be a factor that decisively
survival, 158 patients after first cadaveric kidney transplanta- determines the success of allogenic organ transplanta-
tion were analyzed for the biallelic –174G→C promoter polymor- tion.phism of the IL-6 gene.
Recently, a biallelic polymorphism within the pro-Results. Carriers of the –174C-allele (genotype GC/CC) had
moter region of the IL-6 gene at position 174G→C wasan inferior three-year graft survival (71/104  68.3%; P 
0.0059) with a 3.7-fold increased relative risk of graft loss com- detected, and the C-allele was found to be associated with
pared to carriers of the –174GG-genotype (48/54  88.9%). The lower in vitro and in vivo production of IL-6 [5]. As–174GC/CC-genotype retained its negative impact on graft sur- 174CC homozygosity was found to be underrepresentedvival when other established prognostic factors and further
in patients with systemic-onset juvenile chronic arthritis,cytokine polymorphisms (308TNF-, TGF-1 codon 10 & 25,
592/819/1082IL-10 and 874IFN-) were considered simultane- a substantial clinical impact of this polymorphism was
ously. hypothesized [5]. In clinical transplantation, the 174CC-
Conclusions. Since the clinical impact on transplant out- genotype of the kidney donor was identified as a major
come seems as important as matching for histocompatibility
risk factor for the occurrence of acute rejection episodesantigens, genotyping of the IL-6 174polymorphism may offer
[6]. Even though the relevance of the recipient’s geno-a new method for identifying patients at increased risk of allo-
graft loss. type for acute rejections is still controversial, the 174G-
allele has recently been associated with renoprotection
[7]. However, no data exist regarding long-term graft
survival after allogenic kidney transplantation.Interleukin-6 (IL-6) is a pleiotropic cytokine with a
central role in host defense. It has diverse functions in-
cluding stimulation of the hepatic acute phase response
METHODSand differentiation or activation of macrophages, B- and
Study designT-cells. IL-6 is produced by many different cell types
and, although initially thought to be a pro-inflammatory We investigated the impact of the kidney recipients’
cytokine, it has recently been recognized as having addi- IL-6 174promoter genotype on the three-year allograft
tional anti-inflammatory and immunosuppressive prop- survival and on the occurrence of biopsy-proven acute
rejection episodes during the clinical course. The follow-
ing cytokine promoter polymorphisms were investigated
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Table 1. Genotype and allele frequencies and corresponding
graft survival
Caucasian
controls
N  383 [5]
Patients N  158
3-year graft
Number % Number % survival %
Genotype frequency
GC 169 44.1 72 45.6 69.4
CC 70 18.3 32 20.2 65.6
GC/CC 239 62.4 104 65.8 68.3
GG 144 37.6 54 34.2 88.9
Allele frequency
G-174 457 59.7 180 57.0
C-174 309 40.3 136 43.0
tion at the Medical University of Lu¨beck between 1982
Fig. 1. Kaplan-Meier analysis of kidney allograft survival rates ac-and 1998. Only patients with a cyclosporine (CsA)-based cording to the interleukin-6 (IL-6) promoter region polymorphism
immunosuppression (CsA/Neoral and methylpredni- 174genotype (GG versus CC/GC). P  0.0059 by the log rank test.
solone or CsA/Neoral and azathioprine and methylpred-
nisolone) and a complete follow-up of at least 36 months
were included. Patients who died with functioning grafts
88.9%; P 0.0059, log rank test; Fig. 1). A multifactorialwithin the observation period of 36 months after kidney
Cox regression analysis established that adjustment fortransplantation were excluded from analysis. We analyzed
other prognostic factors such as HLA-matching, sex andall promoter polymorphisms using polymerase chain reac-
age of the donor and recipient, year of transplantation,tion-single strand polymorphism (PCR-SSP; Cytokine
presence of preformed lymphocytotoxic antibodies, andGenotyping Tray; One-Lambda Technologies, Canoga
Park, CA, USA) on a Perkin-Elmer 9600 Thermocycler the occurrence of acute rejection episodes during the
(Perkin-Elmer, Norwalk, CT, USA). The PCR condi- early post-transplant period had no significant influence
tions were: 96C for 130 seconds; 63C for 60 seconds; 9 on this result. When all factors were considered simulta-
cycles of 96C for 10 seconds; 63C for 60 seconds; 20 neously, the CC/CG-genotype retained its negative im-
cycles of 96C for 10 seconds; 59C for 50 seconds; and pact on graft survival (P  0.014). Carriers of the 174C-
72C for 30 seconds. allele were identified as having a 3.7-fold increased rela-
tive risk for graft loss within three years (95% confidence
Statistics
interval 1.3 to 10.5), resulting in a 20.6% difference in
Allograft survival was calculated according to the three-year graft survival compared with 174C-allele neg-
method of Kaplan and Meier. The comparison of the ative patients (genotype GG). Since further cytokine
survival curves was analyzed with the long-rank test. polymorphisms were tested simultaneously, a Bonfer-
Multifactorial Cox regression analysis was performed to roni correction was applied to exclude that the observed
investigate the impact of the other prognostic factors on association resulted by chance (P  0.047). Except for
the observed association of the 174genotype with graft the IL-6 174polymorphism, none of the other cytokine
survival. Since several polymorphisms were tested in par- polymorphisms tested were found to impact long-term
allel, a Bonferroni correction was applied to exclude that
graft survival significantly. Furthermore, acute rejection
our findings resulted by chance.
episodes during the clinical course of the patients were
not associated with the investigated cytokine polymor-
phisms.RESULTS
Both IL-6 174alleles were common in our Caucasian
kidney graft recipients and the genotype/allele frequen-
DISCUSSIONcies were comparable to recently published healthy con-
This study reports, to our knowledge for the first time,trols (P  0.73, global chi-squared test; Table 1) [5].
a significant association of the IL-6 174promoter poly-While the overall three-year graft survival rate was
morphism with long-term kidney allograft survival. Its75.3% (119/158) in our cohort, Kaplan-Meier analysis
clinical impact may be as important as matching for histo-revealed inferior graft survival for the 174GC/CC (71/
104, 68.3%) compared to the 174GG-genotype (48/54, compatibility antigens, since the difference in graft sur-
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Table 2. Cox multifactorial regression analysis In accordance with these observations, our data indicate
that the impact of the kidney recipients’ IL-6 174geno-Variable Coefficient 95% CI
type on allograft outcome may be detectable only whenIL-6 174 genotype 3.7 1.3–10.5
HLA-matching 4.2 1.4–12.3 the long-term course after transplantation is evaluated.
Sex of donor/recipient 1.1 0.4–2.8 One possible explanation could be that the higher dosage
Age of donor 1.2 0.5–2.8
of immunosuppressive drugs, especially corticosteroids,Age of recipient 1.0 0.4–2.5
Years post-transplantation 2.7 1.2–6.1 might disguise the impact of the IL-6 174genotype in the
Preformed antibodies 4.9 1.7–14.0 early phase after transplantation. Moreover, analysis of
Acute rejections 1.1 0.5–2.6
11 cytokine polymorphisms identified the IL-6 174CC-
genotype of the kidney donor as being strongly pre-
dictive of acute rejection within 30 days [10], suggesting
the donor genotype to prevail and to be much more
vival between 174C-allele negative and positive individu-
relevant at this stage. However, replica retrospective
als is almost identical to the 18% difference in five-year
studies of different cohorts and prospective clinical stud-
graft survival of first cadaver kidney transplants with 0 ies including both the recipient and the donor genotype
and 6 HLA-mismatches [8]. Due to the high frequency will be required to confirm that observation. To explain
of the 174C-allele in our Caucasian population, the intro- the potential pathogenetic link between the 174genotype
duction of genotyping into clinical routine may offer a and allograft outcome, we suggest that immunologic
simple method for identifying a significant proportion of mechanisms be considered first, since the 174polymor-
patients at risk of graft loss. phism has been shown to be functionally relevant for
Several published studies already have addressed the the IL-6 gene expression [5]. Functional studies will have
potential impact of cytokine genotypes on solid organ to focus on the three hypotheses: (a) the IL-6 174poly-
transplantation [7, 9–13]. However, these investigations morphism itself is of functional relevance for graft sur-
revealed variable results that may be attributed to the vival; (b) it is in linkage disequilibrium with other flank-
different study designs including: (a) patient group (eth- ing, functionally relevant polymorphisms [16]; and (c) it
nic origin), (b) transplanted organ (cadaveric kidney vs, has an impact on the pharmacodynamic efficacy of the
heart, lung or liver), (c) immunosuppressive protocol immunosuppressive drugs used in our cohort. The inves-
(CsA based versus tacrolimus versus additional thymo- tigation of these hypotheses may provide new insights
globulin), (d) definition of rejection (biopsy-proven), and into the role of IL-6 in the allogenic immune response
(e) observation period (clinical course vs. several months). and tolerance induction.
Thus, a comparison of our findings with the results from In conclusion, we report a significant association of the
different centers is difficult [10]. IL-6 174polymorphism with long-term kidney allograft
The impact of cytokine polymorphisms on long-term survival. Our results imply a protective effect of the
graft survival in patients under CsA-based triple therapy 174G-allele versus the 174C-allele in the multifactorial
has not been subjected to large clinical trials. Previous pathogenesis of allograft rejection.
investigations concentrated on patient cohorts treated
predominantly with CsA monotherapy [13]. These stud- ACKNOWLEDGMENTS
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